我們已在上線! 進一步了解
PRVB

Provention Bio, Inc. Common Stock

已下市

PRVB已於2023年4月26日下市。

 

關於: Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.

員工: 174

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於PRVB的最新新聞文章。

價格圖表採用Lightweight Charts™實作